Literature DB >> 28142066

Prevalence and correlates of DSM-5 major depressive and related disorders in the community.

Caroline L Vandeleur1, Sylfa Fassassi2, Enrique Castelao2, Jennifer Glaus3, Marie-Pierre F Strippoli2, Aurélie M Lasserre2, Dominique Rudaz2, Sirak Gebreab2, Giorgio Pistis2, Jean-Michel Aubry4, Jules Angst5, Martin Preisig2.   

Abstract

Although the DSM-5 has suggested the two new categories of Persistent Depressive Disorders (PDD) and Other Specified Depressive Disorders (OSDD), no study so far has applied the DSM-5 criteria throughout the range of depressive disorders. The aims of the present study were to 1) establish the lifetime prevalence of specific depressive disorders according to the new DSM-5 definitions in a community sample, and 2) determine their clinical relevance in terms of socio-demographic characteristics, comorbidity, course and treatment patterns. The semi-structured Diagnostic Interview for Genetic Studies was administered by masters-level psychologists to a random sample of an urban area (n=3720). The lifetime prevalence was 15.2% for PDD with persistent major depressive episode (MDE), 3.3% for PDD with pure dysthymia, 28.2% for Major Depressive Disorder (MDD) and 9.1% for OSDD. Subjects with PDD with persistent MDE were the most severely affected, followed by those with recurrent MDD, single episode MDD, PDD with pure dysthymia and OSDD and finally those without depressive disorders. Our data provide further evidence for the clinical significance of mild depressive disorders (OSDD), but cast doubt on the pertinence of lumping together PDD with persistent MDE and the former DSM-IV dysthymic disorder within the new PDD category.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Comorbidity; Course; Major depression; Persistent depression; Prevalence; Subthreshold depression; Treatment

Mesh:

Year:  2017        PMID: 28142066     DOI: 10.1016/j.psychres.2017.01.060

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  23 in total

1.  Psychosocial and health-related risk factors for depressive symptom trajectories among midlife women over 15 years: Study of Women's Health Across the Nation (SWAN).

Authors:  Joyce T Bromberger; Laura L Schott; Nancy E Avis; Sybil L Crawford; Sioban D Harlow; Hadine Joffe; Howard M Kravitz; Karen A Matthews
Journal:  Psychol Med       Date:  2018-04-06       Impact factor: 7.723

2.  Fibroblast growth factor 2 regulates activity and gene expression of human post-mitotic excitatory neurons.

Authors:  Shweta Gupta; Tanya M-Redmond; Fan Meng; Andrew Tidball; Huda Akil; Stanley Watson; Jack M Parent; Michael Uhler
Journal:  J Neurochem       Date:  2017-12-27       Impact factor: 5.372

Review 3.  Brain Disorders and Chemical Pollutants: A Gap Junction Link?

Authors:  Marc Mesnil; Norah Defamie; Christian Naus; Denis Sarrouilhe
Journal:  Biomolecules       Date:  2020-12-31

Review 4.  Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders.

Authors:  Rashita Makkar; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Aldulkarim M Meraya
Journal:  Neurotox Res       Date:  2022-04-27       Impact factor: 3.911

5.  Psychiatric Disorders and Substance Use Among African American Women in HIV Care.

Authors:  Heidi E Hutton; Noa Cardin; Keemi Ereme; Geetanjali Chander; Xiaoqiang Xu; Mary E McCaul
Journal:  AIDS Behav       Date:  2020-11

Review 6.  Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder.

Authors:  Oleg A Levada; Alexandra S Troyan
Journal:  Ann Gen Psychiatry       Date:  2017-10-26       Impact factor: 3.455

7.  Criminalization Through Transinstitutionalization: A Critical Review of the Penrose Hypothesis in the Context of Compensation Imprisonment.

Authors:  Sebastian Schildbach; Carola Schildbach
Journal:  Front Psychiatry       Date:  2018-10-25       Impact factor: 4.157

Review 8.  Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use.

Authors:  Helge H O Müller; Sebastian Moeller; Caroline Lücke; Alexandra P Lam; Niclas Braun; Alexandra Philipsen
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

9.  Influence of genetic polymorphisms in homocysteine and lipid metabolism systems on antidepressant drug response.

Authors:  Baoyu Yuan; Xiaoyan Sun; Zhi Xu; Mengjia Pu; Yonggui Yuan; Zhijun Zhang
Journal:  BMC Psychiatry       Date:  2020-08-14       Impact factor: 3.630

10.  Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.

Authors:  Bettina Diekamp; Stephane Borentain; Dong-Jing Fu; Robert Murray; Kristin Heerlein; Qiaoyi Zhang; Cornelius Schüle; Maju Mathews
Journal:  Neuropsychiatr Dis Treat       Date:  2021-07-15       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.